ATLAS Trial: Axitinib in Patients at High Risk of Recurrence of Kidney Cancer
Posted: Friday, November 30, 2018
Marine Gross-Goupil, PhD, of the Centre Hospitalier Universitaire de Bordeaux, France, and colleagues found that axitinib may serve as an alternative to conventional therapies for patients at high risk for recurrent renal cell carcinoma. However, no significant differences between axitinib and placebo in terms of disease-free survival in the intent-to-treat population and lower risk of recurrence subpopulation were reported. These findings were presented at the 2018 European Society for Medical Oncology (ESMO) Congress (Abstract 863O) in Munich.
The researchers enrolled 724 patients: 363 patients received axitinib and 361 received placebo. Most of the patients (73.3%) were Asian, and 56.5% were at high risk for recurrence (defined as pT3 with Fuhrman grade ≥ 3 or pT4 and/or N1 with any Fuhrman grade). In the highest risk for recurrence population, 209 received axitinib and 200 received placebo. The median treatment duration was 19.9 months for axitinib and 21.9 months for placebo.
The investigators found no significant differences between axitinib and placebo in terms of disease-free survival in the intent-to-treat population and the lower risk for recurrence subpopulation. However, there was a significant difference in disease-free survival reported in the highest risk subpopulation. No new safety signals were seen in patients at high risk for recurrent renal cell carcinoma.